Johnson & Johnson (NYSE: JNJ) in Talks With Holdouts to Secure $6.48 Billion Talc Settlement
NEW YORK – On Friday, Johnson & Johnson (NYSE: JNJ) said it is negotiating with plaintiffs’ lawyers who have opposed […]
Johnson & Johnson
US FDA Approves Johnson & Johnson’s Combination Therapy for a Type of Lung Cancer
On Tuesday, the U.S. Food and Drug Administration approved Johnson & Johnson’s (NYSE: JNJ) chemotherapy-free combination treatment for a type
US FDA Approves Johnson & Johnson’s Combination Therapy for a Type of Lung Cancer Read More »
Exclusive: Johnson & Johnson (NYSE: JNJ) Near Disclosing Support For Talc Settlement, Sources Say
NEW YORK – Johnson & Johnson (NYSE: JNJ) is preparing to unveil widespread support in the coming days for a
Johnson & Johnson (NYSE: JNJ) Clears Major Hurdle in $6.5 Billion Talc Settlement
NEW YORK – Johnson & Johnson (NYSE: JNJ) has cleared a key threshold of support for its proposed $6.5 billion
Johnson & Johnson (NYSE: JNJ) Clears Major Hurdle in $6.5 Billion Talc Settlement Read More »
Johnson & Johnson (NYSE: JNJ) Stock Jumps on Strong Q2 Earnings and Revenue Figures
Johnson & Johnson (NYSE: JNJ) reported better-than-expected earnings for the second quarter on Thursday and raised its full-year profit outlook.
Johnson & Johnson (NYSE: JNJ) Stock Jumps on Strong Q2 Earnings and Revenue Figures Read More »
Johnson & Johnson (JNJ) Chooses LAVA Therapeutics (LVTX) for Cancer Study, Stock Surges
LAVA Therapeutics N.V. (NASDAQ: LVTX) experienced a significant surge in its stock prices, rising by almost 36.84% after market hours
Johnson & Johnson (JNJ) Chooses LAVA Therapeutics (LVTX) for Cancer Study, Stock Surges Read More »